Categoria: Adnkronos News

(Adnkronos) – Fast-growing CRO utilizes Veeva Vault Clinical Suite to substantially decrease startup time NEW PROVIDENCE, N.J. and BARCELONA, Spain, May 30, 2023 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Lotus Clinical Research expanded its partnership with Veeva and broadened its adoption of Veeva Vault Clinical Suite, a strategic move to strengthen its service delivery and efficiency. This builds on Lotus' existing use of Vault Clinical Suite to implement swifter and more connected studies. The successful incorporation of Veeva Vault CDMS, Veeva Vault eTMF, and Veeva Vault CTMS has effectively scaled Lotus' trial operations while sustaining the highest quality standards. With a unified clinical ecosystem, Lotus has significantly reduced study startup time. Lotus President, Bill Martin, elaborated on the benefits of the partnership with Veeva, "This collaboration enables Lotus to conduct a higher volume of clinical trials while improving coordination with sponsors and clinical trial sites. Easy-to-use, integrated clinical applications are vital for Lotus as we continue to diversify our disease area expertise and increase our site interactions and patient recruitment." As a rapidly expanding CRO, Lotus sought to develop an adaptable, connected, and scalable infrastructure to keep pace with its growth. The internal team of trained programmers is now leveraging Vault CDMS, its primary clinical data management system, to design studies entirely in-house. This has resulted in faster delivery of electronic data capture (EDC) study builds, significantly cutting study startup time. Using integrated applications on a single platform has enabled Lotus to effortlessly share questionnaires and metrics between Vault CDMS and Vault CTMS, simplifying monitoring reports. With a single source for documentation and a seamless flow of data and documents across clinical applications, Lotus can increase compliance, ensure rapid study initiation, and deliver a better site experience. These advancements have propelled Lotus' transition from a company with an initial focus on acute pain and CNS to one that supports all facets of clinical research. "We're proud to grow our five-plus year partnership with Lotus, bringing together their experience and knowledge executing complex clinical trials with our technology expertise," said Jon Young, director, Veeva Vault Clinical strategy. "With Veeva Vault Clinical Suite, Lotus can provide value-added services to customers and streamline how they work with sites for greater speed and agility." About Lotus Clinical ResearchLotus is a scientifically driven, full-service, consultative CRO delivering across all phases of clinical development with a legacy and focus in CNS research. Since its inception in 2001, Lotus has strategically focused the growth of its services, expertise, and regulatory knowledge to successfully partner with biopharmaceutical companies to execute clinical trials across all indications from Phase 1 through 4. Lotus is unique to other CROs in that they are owned by Emerge Holdco, LLC, which also owns Evolution Research Group, LLC (ERG), a leading clinical site organization with 20+ wholly owned clinical research sites around the US, with over 450 beds, conducting early and late phase complex trials in both healthy volunteers and highly specialized, diverse populations. The successful conduct of clinical trials at Lotus is a result of the therapeutic expertise and the superior level of talent across the medical, operational, and support functions. For more information, visit lotuscr.com.
 About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu. Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.   Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/lotus-clinical-research-expands-partnership-with-veeva-to-accelerate-clinical-trials-301836231.html
 

 —immediapress/ictwebinfo@adnkronos.com (Web Info)

(Adnkronos) –  NASDAQ | TSX: ACB  EDMONTON, AB, May 30, 2023 /PRNewswire/ — Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), and Ethypharm are pleased to announce that they have once again been selected by the French General Directorate of Health (DGS) as exclusive suppliers of dried medical cannabis flower until the end of the French trial period. The trial has recently been extended until March 2024.   "We are delighted to have been selected once again to continue to supply high quality dried medical cannabis flower to the French pilot program. Driven by our purpose of opening the world to cannabis, Aurora continues to work hand-in-hand with government officials, physicians and pharmacists to reduce stigma and further develop medical markets throughout Europe," says Dr. Axel Gille, President of Aurora Europe.  Aurora and Ethypharm signed an agreement to serve the French pilot program, led by the National Agency for the Safety of Medicines and Health Products (ANSM), in October 2020, leveraging both parties' expertise. Under the terms of the exclusive partnership, Aurora supplies medical cannabis, as well as EU GMP (Good Manufacturing Practices) manufacturing and logistics support. Distribution and pharmacovigilance activities continue to be handled by Ethypharm Laboratories, Ethypharm's French sales subsidiary.  Within the framework of the extension of the trial, the DGS opened a call for tenders to supply medical cannabis in January 2023. In March, Aurora Europe and Ethypharm were selected to continue to provide medical cannabis produced according to European GMP standards to patients included in the study.  As committed partners, Ethypharm and Aurora Europe reaffirm their commitment to patients and healthcare professionals to improve the status and accessibility of medical cannabis in Europe.  "By planning to make Aurora's pharmaceutical grade medical cannabis available in France, we wish to reinforce our expertise in Central Nervous System pathologies, and in particular in pain treatment. We are proud to move forward with the French health authorities and health professionals in this experimentation which, we hope, will show the interest of the use of medical cannabis to relieve French patients from certain symptoms such as pain," says Frederic Arnal, General Manager of Ethypharm Laboratories. About Aurora EuropeAurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies high-quality medical cannabis products to patients throughout Europe. Aurora is one of the largest authorised importers and distributors of medical cannabis in the European Union & the UK. Aurora Deutschland, part of Aurora Europe GmbH, is one of three companies licensed to grow medicinal cannabis in Germany. Since May 2022, Aurora Produktions GmbH has been producing one ton of medicinal cannabis annually in Leuna, Saxony-Anhalt. Aurora's internal network of EU GMP facilities delivers high-quality, premium medical cannabis to patients worldwide. For more information please visit www.auroramedicine.com or follow us on www.linkedin.com/company/aurora-europe.
 About Ethypharm Ethypharm is a European pharmaceutical company specializing in two areas: Central Nervous System and Hospital Injectable Drugs. Ethypharm markets its medicines directly in Europe and China, and has partners in North America and the Middle East. The Group employs more than 1,600 people, mainly based in Europe and China.   Ethypharm works closely with the authorities and healthcare professionals to ensure the appropriate use of and access to its medicines for the greatest number of people.   For more information about Ethypharm, visit our website https://www.ethypharm.fr/ and follow us on LinkedIn. This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, the Company's continued participation in the French pilot program and duration of the program, the Company's continued supply of medical cannabis and EU GMP and logistics support, and the Company's ongoing work with, and commitment to, patients and healthcare professionals to improve the status and accessibility of medical cannabis throughout Europe. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances and that could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated September 20, 2022 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.  Media contact: Anke Illigen, Senior Manager Communications Europe, Aurora Europe GmbH, Wilmersdorfer Straße 98/99, 10629 Berlin, M +49 (0) 176 18000 423, T +49 (0)30 9832 1601 0, anke.illigen@auroramedicine.com, www.auroramedicine.com; Avril Ponnelle, Group Communication Manager, Ethypharm, 194 Bureaux de la Colline, 92213 Saint-Cloud Cedex – France, M +33 6 3051 2527, presse@ethypharm.com, www.ethypharm.com
 Logo – https://mma.prnewswire.com/media/2065462/Aurora_Cannabis_Inc__Aurora_and_Ethypharm_Reaffirm_their_Commitm.jpg Logo – https://mma.prnewswire.com/media/2086936/Aurora_Cannabis_Inc__Aurora_and_Ethypharm_Reaffirm_their_Commitm.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/aurora-and-ethypharm-reaffirm-their-commitment-to-promote-access-to-medical-cannabis-for-french-patients-301836178.html
 

 —immediapress/chimica-farmaceuticawebinfo@adnkronos.com (Web Info)

(Adnkronos) – SEONGNAM, South Korea, May 30, 2023 /PRNewswire/ — SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has announced today the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization (MA) for SK bioscience's COVID-19 vaccine SKYCovion™ (brand name in Korea: SKYCovione™) as a primary series for strong immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. It becomes the 8th COVID-19 vaccine authorized by the UK's independent medicines regulator. The authorization covers England, Scotland, and Wales. The MHRA's decision is based on data from the Phase III trial that showed the vaccine induced neutralizing antibody responses against SARS-CoV-2 parental strain and had a standard safety and reactogenicity profile after administered as a primary vaccination of two doses. Jaeyong Ahn, CEO of SK bioscience said, "We are delighted with the MHRA's authorization of Korea's first COVID-19 vaccine SKYCovion. This is the result of our commitment to protecting and promoting global public health. We are confident it will be the milestone to solidify our position in the global market amid the transition of the pandemic to the endemic phase." SKYCovion, the protein-based vaccine developed with GSK's pandemic adjuvant, can be stored between 2-8 degrees Celsius, making it suitable to use in countries where ultra-low cold chain channels are not available. This helps achieving the vaccine equity and vaccination coverage in low-income countries. SK bioscience has also applied for an Emergency Use Listing (EUL) from the World Health Organization (WHO) and Marketing Authorization (MA) from the European Medicines Agency (EMA). SKYCovion is jointly developed with the Institute for Protein Design (IPD) from the University of Washington School of Medicine. The development of SKYCovion has been supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the European Union's Horizon 2020 Programme, and its pre-clinical trials have been funded by the Bill & Melinda Gates Foundation. SKYCovion is the world's first-ever vaccine developed using the RoseTTAFold, a software tool that uses deep learning to quickly and accurately predict protein structures based on limited information. The RoseTTAFold was designed as a three-track neural network developed by the University of Washington. SK bioscience is expanding its portfolio to secure its competitiveness in the endemic phase of the pandemic by developing 1) universal pan-sarbecovirus vaccines funded by CEPI, 2) polyvalent vaccines, and conducting the pre-clinical trials for 3) mRNA vaccine platform development funded by CEPI and the Bill & Melinda Gates Foundation. About SK bioscience SK bioscience is a global innovative vaccine and biotech company, standing committed to global pandemic preparedness in vaccine development and manufacturing to create more equitable access to vaccines. In leveraging strengths on cutting-edge vaccine development technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. Under collaborations of domestic and international governments, regulatory agencies, healthcare providers, doctors and medical experts, SK bioscience has firmly established globally certified R&D and manufacturing technologies. All of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions. 
SK bioscience Homepage
SK bioscience Linkedin
 Media Contact:Changhyun Jin (jin99@sk.com)Jeannie S. Pak (J.pak@sk.com)Tae-Gyun Kim (taegyunkim@sk.com)   Photo – https://mma.prnewswire.com/media/2087946/SKYCovion.jpgLogo – https://mma.prnewswire.com/media/1979527/SK_bioscience_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/sk-bioscience-receives-marketing-authorization-of-covid-19-vaccine-from-uk-mhra-301836968.html
 

 —immediapress/salute-benesserewebinfo@adnkronos.com (Web Info)

(Adnkronos) – Mercoledì a Budapest l’atto finale della competizione, con i giallorossi che cercano il secondo trionfo consecutivo dopo quello in Conference. Nella lavagna per la vittoria contando anche supplementari e rigori, stessa offerta: 1,90  Milano, 30 maggio 2023 – Vincere l’Europa League contro la regina dell’Europa League. Questo il piano diabolico della Roma e di José Mourinho: mercoledì sera, a Budapest, si gioca la finale di una competizione che gli andalusi hanno conquistato sei volte, e che la Roma proverà invece a fare sua un anno dopo il trionfo di Tirana in Conference League. Non sarà facile, perché gli spagnoli dopo una stagione tribolata si sono ripresi grazie anche al lavoro di Mendilibar, il terzo allenatore stagionale, ma la Roma vuole provarci. Le quote Snai vedono in leggerissimo vantaggio il Siviglia, favorito nei 90 minuti a 2,75: il «2» paga 2,90, infine il pareggio – che porterebbe le squadre ai supplementari, visto che fanno fede i tempi regolamentari – a 2,95. Nell’opzione “coppa in mano”, però, l’equilibrio torna perfetto, con Siviglia e Roma (i giallorossi giocano formalmente in trasferta) a 1,90. I bookmaker non si attendono una finale con molti gol: la forbice tra l’Under a 1,48 e l’Over a 2,50 è larghissima, mentre si stringe nell’opzione Goal/No Goal: il risultato con entrambe le squadre a segno paga 2,00, quello con almeno una a secco 1,70. Il risultato più probabile? L’1-1 a 5,75, poi lo 0-0 a 6,75 e l’1-0 a 7,00. La vittoria della Roma con la quota più bassa nei 90’ è lo 0-1 a 7,25.  
Supplementari e rigori E se si andasse oltre? Il Siviglia resta con una punta di vantaggio, visto che il successo ai supplementari si gioca a 9,50, contro il 10 legato alla Roma. Ai rigori, invece, è una lotteria anche nelle quote: 8,50 per Mendilibar, 8,50 per Mourinho.  
Marcatori Tra i possibili marcatori, domina il marocchino En-Nesyri, a 3,00; poi Paulo Dybala, che non è al meglio ma vuole esserci. Un gol dell’argentino vale 3,75, così come per Abraham. Scendendo, si trovano Ocampos e Rafa Mir a 4,50, Belotti e l’ex Lamela a 5,00, poi ancora un quartetto a 6,00 formato da Pellegrini, Bryan Gil, Suso ed El Shaarawy.  Ufficio stampa Snaitech  E-mail: ufficio.stampa@snaitech.it
 Cell: 348.4963434  —immediapress/sportwebinfo@adnkronos.com (Web Info)

(Adnkronos) – XUZHOU, China, May 30, 2023 /PRNewswire/ — XCMG Machinery (SHE:000425) has ranked among the top three in the 2023 AccessM20 List recently released by Access International, the world's largest access manufacturer listing that shows the annual revenue from the previous calendar year for 40 of the largest access equipment producers. XCMG has moved up two places from fifth place in 2021 and maintains the highest ranking among Chinese construction equipment manufacturers.  In 2022, XCMG has fully carried forward its global development roadmap and achieved major sales breakthroughs of aerial work platforms in the markets of North America, Europe, and Asia-Pacific, and it has debuted 10 products from three categories at the bauma 2022 that wowed the international visitors with their intelligent, innovative, and green aerial work solutions. The entire aerial work platform product portfolio of XCMG has passed the strictest CE certification in Europe, the ANSI certification in North America, and the AS/NZS1418 certification in Australia. Now exported to more than 60 countries and regions worldwide, XCMG's high-performance, efficient, safe, and reliable aerial work equipment can meet the various demands of customers from different markets, and the export volume continues to grow rapidly.  XCMG Fire-Fighting Safety Equipment has won a series of awards and recognitions in 2022, including being recognized as a national enterprise with advantages in intellectual property. The XGS28ACK straight boom aerial work platform from the Smart Cloud K series was named one of the "Top 50 Products of China Construction Machinery" in 2022.  Committed to leading industry development with technological innovation, XCMG has significantly invested in developing new products, including the XGS70K, a record-breaking telescopic boom lift.   XCMG continually breaks new ground in the R&D of green and new energy equipment products, and it has released a lineup of high-performance electric products, including the first pure electric articulated boom aerial work platform GTBZ14JD, the flagship models from the Smart Cloud K series XGA22ACK and XGS28ACK, and scissor fork lifts XG1523RT and G1823RT.  "Leveraging years of technological achievements, XCMG is leading the industry's development with major breakthroughs in product safety, sustainability, and maneuverability, which are achieved through intelligent equipment, automated manufacturing, modularized core components, and digitalized management, creating greater value for our customers and partners," said Li Qianjin, Assistant President of XCMG Machinery. For more information about XCMG, please visit http://en.xcmg.com/en-ap/. 
View original content:https://www.prnewswire.co.uk/news-releases/xcmg-machinery-ranks-top-three-in-accessm20-manufacturers-listing-for-its-surging-business-of-the-2022-calendar-year-301837071.html
 

 —immediapress/auto-motoriwebinfo@adnkronos.com (Web Info)